How big is AVITA Medical, Inc.?

As of Jun 18, AVITA Medical, Inc. has a market capitalization of 137.72 million and reported net sales of 71.67 million, with a net profit of -57.05 million for the latest four quarters. Shareholder's funds are 4.50 million, and total assets amount to 79.71 million.

As of Jun 18, AVITA Medical, Inc. has a market capitalization of 137.72 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 71.67 million for the latest four quarters. However, it also recorded a net profit of -57.05 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 4.50 million and total assets amounting to 79.71 million.

What does AVITA Medical, Inc. do?

AVITA Medical, Inc. is a regenerative medicine company focused on developing treatments for burn injuries, chronic wounds, and dermatological conditions. As of March 2025, it reported net sales of $19 million and a net loss of $14 million, with a market cap of $137.72 million.

Overview: <BR>AVITA Medical, Inc. is a regenerative medicine company that develops treatment solutions for burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 19 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -14 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 137.72 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -3.42 <BR>Return on Equity: 1,247.54% <BR>Price to Book: -30.13<BR><BR>Contact Details: <BR>Address: 28159 Avenue Stanford, Suite 220, VALENCIA CA : 91355 <BR>Tel: 1 661 3679170 <BR>Website: https://www.avitamedical.com/

Should I buy, sell or hold AVITA Medical, Inc.?

Who are in the management team of AVITA Medical, Inc.?

As of March 2022, the management team of AVITA Medical, Inc. includes Mr. Lou Panaccio (Independent Non-Executive Chairman), Dr. Michael Perry (CEO and Executive Director), and Independent Non-Executive Directors Mr. Jeremy Cook, Prof. Suzanne Crowe, and Mr. Louis Drapeau. They oversee the company's strategic direction and operations.

As of March 2022, the management team of AVITA Medical, Inc. includes the following individuals:<BR><BR>- Mr. Lou Panaccio, who serves as the Independent Non-Executive Chairman of the board.<BR>- Dr. Michael Perry, who is the Chief Executive Officer and an Executive Director.<BR>- Mr. Jeremy Cook, who is an Independent Non-Executive Director.<BR>- Prof. Suzanne Crowe, who is also an Independent Non-Executive Director.<BR>- Mr. Louis Drapeau, who serves as an Independent Non-Executive Director.<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is AVITA Medical, Inc. overvalued or undervalued?

As of May 13, 2021, AVITA Medical, Inc. is considered risky and overvalued, with poor financial metrics and a year-to-date return of -59.84%, significantly underperforming the S&P 500's 2.44%.

As of 13 May 2021, the valuation grade for AVITA Medical, Inc. has moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of -35.33, an EV to EBIT of -3.46, and an EV to EBITDA of -3.56, all indicating significant financial distress and negative performance.<BR><BR>In comparison to its peers, AVITA Medical's P/E ratio is -2.4152, while CareDx, Inc. is very attractive with a P/E of -58.5934, and AngioDynamics, Inc. also falls under the risky category with a P/E of -21.8992. The stark contrast in valuation metrics among these companies highlights the challenges AVITA faces. Additionally, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -59.84% compared to the index's 2.44%, reinforcing the notion that AVITA Medical is overvalued.

Is AVITA Medical, Inc. technically bullish or bearish?

As of August 19, 2025, AVITA Medical, Inc. is in a bearish trend with moderate strength, indicated by a bearish monthly MACD and poor performance against the S&P 500, showing a year-to-date return of -56.72% compared to the S&P 500's 12.22%.

As of 19 August 2025, the technical trend for AVITA Medical, Inc. has changed from mildly bearish to bearish. The current stance is bearish with moderate strength, driven by a bearish monthly MACD and bearish readings in both the On-Balance Volume (OBV) and KST indicators. While the weekly MACD and Dow Theory show mildly bullish signals, the overall trend remains negative. The stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -56.72% versus the S&P 500's 12.22%, and a one-year return of -46.83% compared to the S&P 500's 17.14%.